nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—Optic nerve disorder—Fludarabine—lymphatic system cancer	0.132	0.132	CcSEcCtD
Tolmetin—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0223	0.0223	CcSEcCtD
Tolmetin—Proteinuria—Fludarabine—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Tolmetin—Protein urine present—Fludarabine—lymphatic system cancer	0.0201	0.0201	CcSEcCtD
Tolmetin—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0164	0.0164	CcSEcCtD
Tolmetin—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Tolmetin—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Tolmetin—Visual disturbance—Fludarabine—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Tolmetin—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.013	0.013	CcSEcCtD
Tolmetin—Tinnitus—Mechlorethamine—lymphatic system cancer	0.013	0.013	CcSEcCtD
Tolmetin—Proteinuria—Mitoxantrone—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Tolmetin—Protein urine present—Mitoxantrone—lymphatic system cancer	0.012	0.012	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Tolmetin—Stomatitis—Teniposide—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Tolmetin—Dysuria—Fludarabine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Tolmetin—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Tolmetin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00987	0.00987	CcSEcCtD
Tolmetin—Renal failure—Fludarabine—lymphatic system cancer	0.00986	0.00986	CcSEcCtD
Tolmetin—Stomatitis—Fludarabine—lymphatic system cancer	0.00978	0.00978	CcSEcCtD
Tolmetin—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00975	0.00975	CcSEcCtD
Tolmetin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00967	0.00967	CcSEcCtD
Tolmetin—Haematuria—Fludarabine—lymphatic system cancer	0.00956	0.00956	CcSEcCtD
Tolmetin—Epistaxis—Fludarabine—lymphatic system cancer	0.00946	0.00946	CcSEcCtD
Tolmetin—Visual impairment—Fludarabine—lymphatic system cancer	0.00868	0.00868	CcSEcCtD
Tolmetin—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Tolmetin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00851	0.00851	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00833	0.00833	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.008	0.008	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00774	0.00774	CcSEcCtD
Tolmetin—Chest pain—Teniposide—lymphatic system cancer	0.00759	0.00759	CcSEcCtD
Tolmetin—Weight decreased—Bleomycin—lymphatic system cancer	0.00746	0.00746	CcSEcCtD
Tolmetin—Oedema—Teniposide—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Tolmetin—Stomatitis—Bleomycin—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Tolmetin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00713	0.00713	CcSEcCtD
Tolmetin—Haematuria—Bleomycin—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Tolmetin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00676	0.00676	CcSEcCtD
Tolmetin—Dysuria—Vincristine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Tolmetin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Tolmetin—Oedema—Fludarabine—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Tolmetin—Renal failure—Carmustine—lymphatic system cancer	0.00631	0.00631	CcSEcCtD
Tolmetin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Tolmetin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Tolmetin—Stomatitis—Carmustine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Tolmetin—Urinary tract infection—Carmustine—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Tolmetin—Weight decreased—Vincristine—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Tolmetin—Weight increased—Mitoxantrone—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Tolmetin—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Tolmetin—Stomatitis—Vincristine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Tolmetin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Tolmetin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Tolmetin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Tolmetin—Nausea—Mechlorethamine—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Tolmetin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Tolmetin—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Tolmetin—Urticaria—Teniposide—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Tolmetin—Glossitis—Methotrexate—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Tolmetin—Body temperature increased—Teniposide—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Tolmetin—Abdominal pain—Teniposide—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Tolmetin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Tolmetin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Tolmetin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Tolmetin—Visual impairment—Carmustine—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Tolmetin—Constipation—Fludarabine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Tolmetin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Tolmetin—Asthenia—Teniposide—lymphatic system cancer	0.00522	0.00522	CcSEcCtD
Tolmetin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Tolmetin—Diarrhoea—Teniposide—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Tolmetin—Chest pain—Bleomycin—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Tolmetin—Oedema—Bleomycin—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Tolmetin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Tolmetin—Vomiting—Teniposide—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Tolmetin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Tolmetin—Asthenia—Fludarabine—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Tolmetin—Headache—Teniposide—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Tolmetin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Tolmetin—Nausea—Teniposide—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Tolmetin—Chest pain—Carmustine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Tolmetin—Oedema—Carmustine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Tolmetin—Visual disturbance—Methotrexate—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Tolmetin—Vomiting—Fludarabine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Tolmetin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Tolmetin—Headache—Fludarabine—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Tolmetin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Tolmetin—Oedema—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Tolmetin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Tolmetin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Tolmetin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Tolmetin—Oedema—Mitoxantrone—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Tolmetin—Nausea—Fludarabine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Tolmetin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Tolmetin—Urticaria—Bleomycin—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Tolmetin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Tolmetin—Somnolence—Carmustine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Tolmetin—Constipation—Carmustine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Tolmetin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Tolmetin—Asthenia—Bleomycin—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Tolmetin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Tolmetin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Tolmetin—Constipation—Vincristine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Tolmetin—Constipation—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Tolmetin—Abdominal pain—Carmustine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Tolmetin—Body temperature increased—Carmustine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Tolmetin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Tolmetin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Tolmetin—Abdominal pain—Vincristine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Tolmetin—Body temperature increased—Vincristine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Tolmetin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Tolmetin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Tolmetin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Tolmetin—Vomiting—Bleomycin—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Tolmetin—Asthenia—Carmustine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Tolmetin—Renal failure—Methotrexate—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Tolmetin—Haematuria—Methotrexate—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Tolmetin—Asthenia—Vincristine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Tolmetin—Diarrhoea—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Tolmetin—Nausea—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Tolmetin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Tolmetin—Dizziness—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Tolmetin—Diarrhoea—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Tolmetin—Hepatitis—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Tolmetin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Tolmetin—Vomiting—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Tolmetin—Dizziness—Vincristine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Tolmetin—Visual impairment—Methotrexate—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Tolmetin—Headache—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Tolmetin—Vomiting—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Tolmetin—Headache—Vincristine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Tolmetin—Nausea—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tolmetin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Tolmetin—Headache—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Tolmetin—Nausea—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Tolmetin—Nausea—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Tolmetin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tolmetin—Somnolence—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tolmetin—Dyspepsia—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Tolmetin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Tolmetin—Urticaria—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Tolmetin—Asthenia—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Tolmetin—Vomiting—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Tolmetin—Headache—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Tolmetin—Nausea—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
